Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Twist Bioscience ( (TWST) ) has issued an update.
At its Annual Meeting, Twist Bioscience’s stockholders approved several key amendments, including increasing the authorized shares by 100,000,000 and allowing officer exculpation under Delaware law. These changes, effective February 10, 2025, were accompanied by the election of three directors, approval of executive compensation, and ratification of Ernst & Young LLP as the accounting firm for the fiscal year ending September 30, 2025. The amendments are expected to impact the company’s operational flexibility and governance structure positively.
More about Twist Bioscience
YTD Price Performance: 7.33%
Average Trading Volume: 872,591
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.12B
See more insights into TWST stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue